ICVHealth Scientific Director Involved in New Personalized Medicine Project (GOING-FWD)
February 1, 2019
Gender Outcomes INternational Group: to Further Well-being Development (GOING-FWD) is a Data Science, Personalized Medicine project funded by Canadian Institutes of Health and Research (CIHR) and GENDER-NET+, a European initiative part of the EU H2020 initiative for a total of one million Euros (Approx. 1,65 Million $CAD). GOING-FWD is led and coordinated at the RI-MUHC by Dr. Louise Pilote, James McGill Professor of Medicine, Dr Valeria Raparelli,Visiting Professor of Medicine at McGill University from Sapienza University of Rome, and Dr. Colleen Norris, Professor in Nursing, Medicine and Public Health Science, University of Alberta. This project involves Dr. Karin Humphries, Associate Professor of Medicine, UBC Faculty of Medicine, UBC-Heart and Stroke Professor in Women’s Cardiovascular Health, and Scientific Director of the BC Centre for Improved Cardiovascular Health.
GENDER-NET+ aims to promote the integration of sex and gender analysis into research. This integration gives new knowledge and insights, which ultimately will benefit both women and men.
A large volume of data gathered through 5-country network (Austria, Canada, Cyprus, Spain, Sweden) will allow for the creation of innovative algorithms that will assist in the implementation of personalized interventions for the management of noncommunicable diseases such as cardiovascular, chronic kidney or neurodegenerative diseases.
Scientific Summary of the Project:
Background: Beyond biological sex, gender is increasingly recognized as a pivotal determinant of health. However, there are no standardized gender measurements. We hypothesize that gender-related factors and their effect will vary substantially between countries and diseases.
Aims: The overarching aims of this large Consortium are to integrate sex and gender dimensions in applied health research, to evaluate their impact on clinical cost-sensitive outcomes and patients reported outcomes related to quality of life in noncommunicable diseases including cardiovascular disease, metabolic disease, chronic kidney disease and neurological disease. We also aim to construct innovative ways to disseminate the application of gender measurement towards personalized approaches to chronic disease prevention, diagnosis and treatment.
Methods: With a five-country transatlantic network comprised of 30 investigators, we will benchmark innovative solutions to measure gender in retrospective cohorts. Based on consensus, we will develop a framework to identify gender-related factors, as well as cost-sensitive and patient-reported outcomes, and measure their associations in 32 accessible cohorts of patients affected by cardiovascular, chronic kidney and neurological diseases and metabolic syndrome. Large database analysis and when appropriate machine learning approaches will allow the derivation of pan and within country disease-specific gender scores which will be validated through e-Health and m-Health applications in prospective disease groups. Educational modules will be developed to promote awareness, implementation and dissemination.
Innovation: As a five-country multidisciplinary Consortium with access to granular large databases, we are uniquely positioned to harness an innovative methodology that will provide a framework to close gender gaps in chronic disease management and promote knowledge transfer in the scientific community and clinical practice.
Stay tuned! For any further information, please contact: GOINGFWD2019@outlook.com